Some of the 16 core AR-binding targets identified in Sharma et al. (2013) have been studied as markers for prostate cancer, either by mutation (XRCC3; Xuan, Hui & Fang, 2015) or increased splice variant expression (AGR2; Neeb et al., 2014). The gene discussed is AR; the disease is prostate cancer.